XTRA:MGNK

Stock Analysis Report

Executive Summary

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases.

Rewards

Loading interface...

Risk Analysis

Loading interface...

Snowflake Analysis

High growth potential and slightly overvalued.

Share Price & News

How has Mologen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

-26.5%

MGNK

6.2%

DE Biotechs

1.0%

DE Market


1 Year Return

-95.1%

MGNK

10.1%

DE Biotechs

14.2%

DE Market

Information is not available.

Information is not available.


Shareholder returns

MGNKIndustryMarket
7 Day-26.5%6.2%1.0%
30 Day-86.2%17.2%0.04%
90 Day-84.4%9.1%6.0%
1 Year-94.9%-95.1%10.3%10.1%17.8%14.2%
3 Year-98.1%-98.3%80.4%78.3%19.2%8.7%
5 Year-99.5%-99.6%15.6%13.2%36.0%17.5%

Price Volatility Vs. Market

How volatile is Mologen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mologen undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is Mologen forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

192.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Mologen performed over the past 5 years?

5.5%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Mologen's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is Mologen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Information is not available.

Information is not available.


Stability and Growth of Payments

Information is not available.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of Mologen's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average board tenure


CEO

Stefan Manth (63yo)

0.6yrs

Tenure

€59,000

Compensation

Dr. Stefan M. Manth, M.D., Ph.D., MBA, has been Chief Executive Officer of Genelux Europe and President of Genelux Europe at Genelux Corporation since July 1, 2013. Dr. Manth served as Partner and Change L ...


Board Age and Tenure

1.5yrs

Average Tenure

Information is not available.


Insider Trading

Information is not available.


Ownership Breakdown

Information is not available.


Management Team

  • Burghardt Wittig

    Co-Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: €576.00k
  • Stefan Manth (63yo)

    CEO & Member of the Executive Board

    • Tenure: 0.6yrs
    • Compensation: €59.00k
  • Matthias Baumann (61yo)

    Chief Medical Officer & Member of Executive Board

    • Tenure: 2.6yrs
    • Compensation: €346.00k
  • Claudia Nickolaus

    Head of Investor Relations & Corporate Communications

    • Tenure: 0yrs

Board Members

  • Burghardt Wittig

    Co-Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: €576.00k
  • Ulrich Granzer (58yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Oliver Krautscheid (51yo)

    Chairman of the Supervisory Board

    • Tenure: 5.3yrs
    • Compensation: €78.00k
  • Dirk Arnold

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Viktor Grünwald

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Schultz

    Member of the Supervisory Board

    • Tenure: 1.5yrs
    • Compensation: €23.00k
  • Friedrike Zahm

    Member of the Supervisory Board

    • Tenure: 0.9yrs

Company Information

Mologen AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mologen AG
  • Ticker: MGNK
  • Exchange: XTRA
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.729m
  • Shares outstanding: 12.44m
  • Website: https://www.mologen.com

Number of Employees


Location

  • Mologen AG
  • Fabeckstrasse 30
  • Berlin
  • Berlin
  • 14195
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGNKDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1999
0IYNLSE (London Stock Exchange)YesOrdinary SharesGBEURJun 1999
MGNKXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURJun 1999
MGNKDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1999
MGNDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1999

Biography

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 21:14
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.